NO20076391L - Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin - Google Patents

Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin

Info

Publication number
NO20076391L
NO20076391L NO20076391A NO20076391A NO20076391L NO 20076391 L NO20076391 L NO 20076391L NO 20076391 A NO20076391 A NO 20076391A NO 20076391 A NO20076391 A NO 20076391A NO 20076391 L NO20076391 L NO 20076391L
Authority
NO
Norway
Prior art keywords
compositions
methods
efrine
cupredoxin
signals
Prior art date
Application number
NO20076391A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Arsenio Fialho
Anita Chaudhari
Yonghua Zhu
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20076391L publication Critical patent/NO20076391L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til sammensetninger og fremgangsmåter for anvendelse av kupredoksiner og varianter, derivater og strukturelle ekvivalenter av kupredoksiner som interfererer med efrinsignalsystemet i mammalske celler. Spesifikt er oppfinnelsen relatert til sammensetninger og fremgangsmåter som anvender kupredoksiner slik som azurin, rusticyanin og plastocyanin og varianter, derivater og strukturelle ekvivalenter derav, for å behandle cancer i pattedyr.
NO20076391A 2005-05-20 2007-12-11 Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin NO20076391L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
PCT/US2006/019684 WO2007018671A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Publications (1)

Publication Number Publication Date
NO20076391L true NO20076391L (no) 2008-02-15

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076391A NO20076391L (no) 2005-05-20 2007-12-11 Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin

Country Status (10)

Country Link
EP (1) EP1888106A4 (no)
JP (1) JP2008539795A (no)
KR (1) KR20080040631A (no)
AU (1) AU2006277009A1 (no)
BR (1) BRPI0612424A2 (no)
CA (1) CA2608512A1 (no)
IL (1) IL187138A0 (no)
MX (1) MX2007014598A (no)
NO (1) NO20076391L (no)
WO (1) WO2007018671A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
WO2006088508A2 (en) 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
MX2008000994A (es) 2005-07-19 2008-03-19 Univ Illinois Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos.
AU2006284490A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
KR20090059152A (ko) * 2006-09-14 2009-06-10 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 암을 예방하는 조성물과 방법
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
RU2525133C2 (ru) 2007-08-30 2014-08-10 Дайити Санкио Компани, Лимитед Антитело к epha2
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2023205752A2 (en) * 2022-04-22 2023-10-26 University Of Miami Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100955973B1 (ko) * 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Also Published As

Publication number Publication date
EP1888106A4 (en) 2009-01-14
WO2007018671A3 (en) 2007-11-22
JP2008539795A (ja) 2008-11-20
EP1888106A2 (en) 2008-02-20
WO2007018671A2 (en) 2007-02-15
MX2007014598A (es) 2008-02-07
AU2006277009A1 (en) 2007-02-15
IL187138A0 (en) 2008-02-09
CA2608512A1 (en) 2007-02-15
KR20080040631A (ko) 2008-05-08
BRPI0612424A2 (pt) 2009-01-27

Similar Documents

Publication Publication Date Title
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
ME01285A (me) Derivati dioksa-bicikl0[3.2.1]oktan-2,3,4-triola
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
NO20083153L (no) Kjemiske forbindelser
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20061194L (no) Mitotiske kinesininbibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20082509L (no) Pyridopyrazinderivater og deres anvendelse
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
EA200601894A1 (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2007111948A3 (en) Inhibitors of protein prenyltransferases
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application